课题基金 / 基金详情

项目摘要

项目成果

MARK H. TUSZYNSKI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Gene therapy may benefit human neurological disorders such as Alzheimer~s disease (AD). Grafting cells to the brain that are genetically modified to produce neurotrophic factors, neurotransmitters or other therapeutic agents can achieve specific intraparenchymal drug delivery in a chronic and well-tolerated manner. In AD, gene therapy could provide a means for delivering neurotrophic factors such as NGF to degenerating neurons in the cholinergic basal forebrain and other regions, or for augmenting neurotransmitter function in the cortex, hippocampus, and other regions. Gene therapy could also ultimately provide a means of manipulating the expression of various genes involved in generating AD pathology. In the first five-year period of this grant, optimal parameters for transducing primary primate cells to produce neurotrophic factors and neurotransmitters in vitro have been developed. Optimal conditions for grafting genetically modified cells to the brain have been established. When grafted to the cholinergic basal forebrain, NGF-producing cells express NGF protein and prevent cholinergic neuronal degeneration for at least 8 months. New models of spontaneous age-related cholinergic neuronal degeneration have also been characterized. The next five-year period of this primate project will determine 1) whether NGF gene therapy will prevent lesion-induced and spontaneous age-related declines in basal forebrain cholinergic neuronal morphology and behavioral function for prolonged periods of up to two years, 2) if neurotransmitter replacement by gene therapy will ameliorate lesion-induced and spontaneous age-related declines in cholinergic biochemistry and behavioral function, as recently shown in rats, and 3) if the in vivo efficacy and safety of gene therapy for future clinical trials in AD can be enhanced by serial MRI and PET imaging, use of regulatable promoters for controlling in vivo gene expression, and direct in vivo genetic modification of primary nervous system cells such as neurons and glia by adenovirus, adeno-associated virus, and HIV vectors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advancing human neural progenitor cells (hNPCs) to FDA IND approval
  • 批准号:
    10642228
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2023
  • 负责人:
    MARK H. TUSZYNSKI
  • 依托单位:
The Primate Corticospinal Connectome and Transcriptome - Supplement
A Clinical Trial of AAV2-BDNF Gene Therapy in Alzheimer's Disease
A Clinical Trial of AAV2-BDNF Gene Therapy in Alzheimer's Disease
国内基金
海外基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
  • 批准号:
    81000622
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2010
  • 负责人:
    梁胜
  • 依托单位:
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
  • 批准号:
    31060293
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    26.0万元
  • 批准年份:
    2010
  • 负责人:
    郭亚芬
  • 依托单位:
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究